Resistance is rarely futile – reinvigorating the AMR ecosystem
Might we defeat our oldest enemy in fighting one of the newest? Peter Jackson looks at how lessons learned from the COVID-19 pandemic can support the development of new treatments for antimicrobial resistance and other infectious diseases.
During a series of lectures at the Museum of London in 2018, Professor Chris Whitty described infectious diseases as our ‘oldest enemy’ – one that throughout time has remained a pivotal element in both medicine and morbidity.
Whitty outlined the threat and, given his appointment a year later as England’s Chief Medical Officer, could well have imagined making speeches about the risks of infections crossing borders in our globalised world. Yet, COVID-19 has surely surpassed even his predictions of the challenges involved in tackling a pandemic that has given us all a harsh lesson in preparedness.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.